- Home
- JBDI vs TPST Comparison
JBDI vs TPST Comparison
Compare JBDI & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JBDI | TPST |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 15.1M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | JBDI | TPST |
|---|---|---|
| Price | $1.04 | $2.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.1M | 90.3K |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,445,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.49 | $2.17 |
| 52 Week High | $3.00 | $12.48 |
Technical Indicators
Market Signals| Indicator | JBDI | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 68.64 | 28.70 |
| Support Level | $0.52 | $2.55 |
| Resistance Level | $1.35 | $3.00 |
| Average True Range (ATR) | 0.14 | 0.23 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 59.63 | 3.06 |
Price Performance
Historical ComparisonAbout JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. It's in the trading of reconditioned and recycling containers in Singapore and the Southeast Asia region. The company offers reconditioning and recycling drums, including open top drums, metal drums, plastic drums, plastic carboys, and intermediate bulk containers, as well as new drums, and collects waste drums and related products. It serves solvent, chemical, petroleum, and edible product oil industries.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.